Between Keto and Ozempic: The 50-Year-Old Weight Loss Medication Australia Keeps Overlooking

Walk into almost any conversation about weight loss in Australia in 2026 and you will hear two things. You will hear somebody talking about the latest eating framework, keto or carnivore or a variation of intermittent fasting. And you will hear somebody talking about Ozempic, Mounjaro, or Wegovy, usually with a mix of curiosity and sticker shock.

What you are much less likely to hear is a conversation about phentermine. The medication, sold in Australia under the brand name Duromine, has been approved by the Therapeutic Goods Administration since the 1970s. It costs a fraction of the newer injectables, works well for a specific kind of patient, and quietly produces clinically meaningful weight loss in the people it suits.

And yet it sits almost invisible in the Australian weight-loss conversation, eclipsed by a newer, louder, and far more expensive cohort of medications that are not necessarily better for the person sitting across from a GP asking what their options are.

The reason phentermine got forgotten is not clinical. It is commercial and historical, and it is worth understanding if you are trying to make an informed decision about medical weight management.

How a Working Medication Ended Up in the Shadows

In 1997, a diet drug combination called fen-phen was pulled from the market after it was linked to heart valve damage and pulmonary hypertension. The culprit turned out to be fenfluramine, the other half of the combination. Phentermine itself was cleared and remained on the approved medications list in Australia, the United States, the United Kingdom, and most developed markets. But the reputational damage was done. Weight-loss medication as a category carried a long shadow for about two decades.

Phentermine is also a generic drug. The patent expired long ago, there is no brand budget behind it, and no pharmaceutical company has a commercial incentive to push it. Meanwhile, the newer GLP-1 medications, originally developed for type 2 diabetes and later trialled for weight loss, arrived with enormous marketing investment and a very public wave of celebrity adoption. Attention followed the money. Clinical conversation followed attention.

The result is that in 2026, many Australians asking about weight-loss medication are directed, sometimes implicitly, toward an expensive long-term injectable before older options are seriously discussed. That is not always appropriate.

What Phentermine Actually Does, and for Whom

Phentermine is an appetite suppressant that works on the central nervous system. It prompts the release of noradrenaline and, to a lesser extent, dopamine, which reduces hunger signalling through the hypothalamus. Cochrane and other systematic reviews have consistently found that it produces around three to five kilograms of additional weight loss over twelve weeks compared with placebo, in people who combine it with reduced-calorie eating and activity.

That number is less dramatic than the figures reported for GLP-1 drugs. But raw weight-loss magnitude is the wrong comparison, because the two medication classes serve different patient profiles.

Phentermine works best for people whose weight pattern is driven by what clinicians sometimes call food noise, the constant background cognitive pull toward food that makes adherence to a sensible eating plan feel exhausting. It suits people in a moderate BMI range, typically 27 to 35, who want a defined intervention window rather than a lifetime prescription, and who are willing to use the twelve-week course to install habit changes they can carry forward.

GLP-1 medications, by contrast, are generally the stronger choice for higher-BMI patients, those with metabolic syndrome or type 2 diabetes, and patients who accept ongoing medication as part of long-term management. They are expensive, often above three hundred dollars a month out of pocket without Pharmaceutical Benefits Scheme subsidy, and supply has been repeatedly disrupted since 2022 as global demand has outpaced manufacturing capacity.

For a subset of Australians, phentermine is the more proportionate medical intervention. It is also the more affordable one, typically under thirty dollars a week when dispensed through a registered Australian pharmacy.

Why People Regain Weight, and Why That Is Not the Drug's Failure

The most common criticism of phentermine, and of short-course weight-loss medications generally, is that weight returns once the prescription ends. This is true. It is also true of every short-course weight-loss intervention, including fad diets, liquid replacement programs, and the first few weeks off a GLP-1 prescription when the appetite drive reinstates.

The problem is not the medication. The problem is what the medication was asked to do.

Phentermine creates a twelve-week window in which appetite is dampened and eating a smaller quantity of food feels tolerable rather than miserable. If that window is used to build durable behaviour, to establish a protein-anchored meal rhythm, a realistic activity pattern, a sleep schedule, and a relationship with hunger that is calmer than it was before, then the weight that comes off during the course has a decent chance of staying off.

If that window is used only to lose weight, with no structural change underneath, then the weight returns as soon as the biology reasserts itself. The medication did its job. The scaffolding was missing.

This is where the nutrition piece becomes essential, and where short-course medication interventions live or die. A practical, sustainable eating pattern during the active treatment phase typically includes:

• A clear protein target at each meal (roughly twenty-five to forty grams)
• A deliberate reliance on whole foods to maintain micronutrient intake while total food volume drops
• Structured meal timing rather than grazing
• Attention to hydration, because phentermine can blunt the thirst signal

Resistance training alongside the course matters more than cardio for preserving lean tissue in a deficit.

None of this is exciting. It is, however, what determines whether the twelve weeks becomes a platform or a detour.

Who Phentermine Is Not For

Responsible clinical prescribing rules out phentermine in several situations. A history of cardiovascular disease, uncontrolled high blood pressure, hyperthyroidism, glaucoma, or a substance use history makes it inappropriate. Pregnancy and breastfeeding are contraindications. The medication cannot be combined safely with certain antidepressants or stimulants. This is why assessment and screening before a prescription are not paperwork. They are the point.

If any of those apply, a different pathway is the correct one. GLP-1 medications may be suitable for some of these patients, and for others the honest conversation with a GP is about what non-pharmacological structure can be built.

Accessing Phentermine in Australia

Phentermine is a Schedule 4 medicine in Australia, meaning it requires a prescription from an authorised prescriber and must be dispensed by a registered Australian pharmacy. A legitimate pathway involves a clinical consultation, cardiovascular screening, and a pharmacist review before the medication is supplied.

Some Australians prefer an end-to-end regulated telehealth service that handles the prescriber consultation and pharmacy dispensing within a single flow, which can be faster and less logistically awkward than bouncing between a GP appointment and a retail pharmacy. duromine australia is one example of that model, where the prescriber and pharmacist layers are intact but the process is consolidated into a single regulated service. The non-negotiable piece is that both the clinical review and the pharmacy dispensing are present. Any source that skips either is not a shortcut, it is a different and more dangerous product.

What Australia's Weight-Loss Conversation Is Missing

The current public discussion about weight-loss medication in Australia is running on two speeds. At one end, the cultural churn of diet trends that most evidence suggests do not work long-term for most people. At the other, an expensive and heavily marketed class of injectable medications that suit a specific patient profile and cost most Australians more per month than their electricity bill.

There is a middle option. It has been there for fifty years. It is cheaper, it is oral, it is time-limited by design, and for the right patient with the right nutrition and lifestyle scaffolding, it does exactly what a weight-loss medication is supposed to do.

Phentermine is not the answer for everyone. It is also not the problem people sometimes assume it is. A good weight-loss conversation in Australia should include it, and at the moment, most of them do not.